سعر جاكاراندا 0.5مجم 2 قرص 2024

Cabergoline 0.5 mg tablets (2 tablets), an ergot-derived dopamine D2 agonist that lowers prolactin.

• Hyperprolactinaemic disorders, idiopathic or due to pituitary adenomas, in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (incidence > 10%): nausea, headache and dizziness.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Uncontrolled hypertension.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to ergot derivatives.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• History of cardiac valvular disorders (anatomical evidence of valvulopathy) or pericardial fibrosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Cardiac valvulopathy and pericardial fibrosis: evaluate with echocardiography before starting and monitor at 6- to 12-month intervals; discontinue if valvular disease develops.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Pleural, pulmonary and retroperitoneal fibrosis; orthostatic hypotension; impulse-control disorders and compulsive behaviours.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• US label: avoid use for inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Dopamine D2 antagonists (phenothiazines, butyrophenones, thioxanthenes, metoclopramide)Concomitant use is not recommended.DailyMed (U.S. National Library of Medicine)

• If conception occurs, discontinue if risks to mother or fetus outweigh benefits; in general avoid dopamine agonists in pregnancy and the postpartum period (higher risk with pregnancy-induced hypertension, pre-eclampsia, eclampsia). Case reports have not shown a clear association with major birth defects.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Not recommended in postpartum women who are breastfeeding or planning to breastfeed.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Cabergoline: Long-acting dopamine D2 receptor agonist; inhibits prolactin secretion from pituitary lactotrophs.